BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 8955198)

  • 1. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
    Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
    J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules.
    Hammond C; Denzin LK; Pan M; Griffith JM; Geuze HJ; Cresswell P
    J Immunol; 1998 Oct; 161(7):3282-91. PubMed ID: 9759843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced interaction of HLA-DM with HLA-DR in enlarged vacuoles of hereditary and infectious lysosomal diseases.
    Lem L; Riethof DA; Scidmore-Carlson M; Griffiths GM; Hackstadt T; Brodsky FM
    J Immunol; 1999 Jan; 162(1):523-32. PubMed ID: 9886429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.
    Kropshofer H; Vogt AB; Thery C; Armandola EA; Li BC; Moldenhauer G; Amigorena S; Hämmerling GJ
    EMBO J; 1998 Jun; 17(11):2971-81. PubMed ID: 9606180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intracellular transport of MHC class II molecules in the absence of HLA-DM.
    Green JM; DeMars R; Xu X; Pierce SK
    J Immunol; 1995 Oct; 155(8):3759-68. PubMed ID: 7561080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J; König A; Koch N
    Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
    Hitzel C; van Endert P; Koch N
    J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
    Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
    J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DR/CLIP (class II-associated invariant chain peptides) and DR/peptide complexes colocalize in prelysosomes in human B lymphoblastoid cells.
    Stang E; Guerra CB; Amaya M; Paterson Y; Bakke O; Mellins ED
    J Immunol; 1998 May; 160(10):4696-707. PubMed ID: 9590215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of two peptide/MHC II isomers is catalyzed differentially by HLA-DM.
    Belmares MP; Busch R; Mellins ED; McConnell HM
    Biochemistry; 2003 Jan; 42(3):838-47. PubMed ID: 12534297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
    Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
    Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assembly of an abundant endogenous major histocompatibility complex class II/peptide complex in class II compartments.
    Morkowski S; Raposo G; Kleijimeer M; Geuze HJ; Rudensky AY
    Eur J Immunol; 1997 Mar; 27(3):609-17. PubMed ID: 9079799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens.
    Cheng PC; Steele CR; Gu L; Song W; Pierce SK
    J Immunol; 1999 Jun; 162(12):7171-80. PubMed ID: 10358163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
    Vigna JL; Smith KD; Lutz CT
    J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
    Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
    J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of peptide binding to DR molecules by a leupeptin-induced invariant chain fragment.
    Demotz S; Danieli C; Wallny HJ; Majdic O
    Mol Immunol; 1994 Aug; 31(12):885-93. PubMed ID: 8065372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inability of the nonobese diabetic class II molecule to form stable peptide complexes does not reflect a failure to interact productively with DM.
    Peterson M; Sant AJ
    J Immunol; 1998 Sep; 161(6):2961-7. PubMed ID: 9743359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.